Introduction {#sec0001}
============

In addition to acute respiratory complications, coronavirus disease 2019 (COVID-19) also causes significant consequences for the cardiovascular system, particularly arrhythmia.[@bib0001] ^,^ [@bib0002] Due to the panoply of precipitating factors that can cause cardiac arrhythmia in COVID-19 patients, identifying the underlying culprit is crucial for proper management. Herein, we describe the course of a COVID-19 patient who experienced an electrical storm of ventricular fibrillation (VF).

Case Presentation {#sec0002}
=================

A 55-year-old woman with history significant for ischemic cerebral vascular infarction (6 years prior) presented with expressive aphasia and stroke-like symptoms. Computed tomography head scan ruled out acute cerebral stroke. Vital signs, laboratory data, and electrocardiogram are in [Table 1](#tbl0001){ref-type="table"} . Urine analysis was positive for bacteriuria. At screening, she tested positive for COVID-19. At that time she was not complaining of any constitutional or respiratory symptoms. She was admitted for cerebral vascular stroke workup and was started on intravenous ceftriaxone for urinary tract infection. Following admission, she became severely hypotensive and experienced worsening leukocytosis and renal function, causing concern for septic shock. Further laboratory workup revealed high interleuken 6 (16.4 pg/mL, upper limit normal = 1.8 pg/mL). She was transferred to the intensive care unit, where circulatory support and corticosteroids were initiated. She experienced sinus bradycardia with a heart rate of 40 beats per minute and was subsequently started on a dopamine infusion. Later that day, she went into cardiac arrest due to Torsades de Pointe (TdP) ([Figure 1](#fig0001){ref-type="fig"} ). A 200 joules shock was delivered, the patient regained sinus rhythm, and was subsequently intubated; her QTc interval was 535ms. A lidocaine infusion and aggressive empiric magnesium supplementation were initiated. While receiving dopamine and lidocaine infusions, she remained bradycardic and experienced another VF and TdP cardiac arrest requiring defibrillation; transcutaneous pacing was started. Convalescent serum was administered as her inflammatory markers continued to rise along with worsening circulatory and respiratory failure. Despite dopamine, lidocaine, and transcutaneous pacing, she had multiple VF arrests requiring more than 60 defibrillator shocks. Her echocardiogram revealed normal left ventricular wall motion with normal function. Serial troponin levels were assessed, peaking at 0.064 ng/mL. At that point, the family signed comfort care only, the patient was extubated, and infusions stopped. Miraculously, she dramatically improved, with QTc improving from \> 700 ms to 500 ms. The repeat echocardiogram did not reveal significant changes. The patient was never treated with hydroxychloroquine or azithromycin. She did not have any additional arrhythmias for the duration of her hospital stay. QTc interval returned to baseline. She had a full recovery and was discharged home on a life vest with plans for outpatient genetic tests for QTc prolongation. On a 4-week follow-up, her EKG showed normal QRS/QTC and she felt great without palpitations, syncope, or life vest shocks.Table 1Vital signs, Laboratory data and electrocardiogram parameters.Table 1Time of ObservationVariablePresentationVentricular FibrillationDischargeBlood pressure (mmHg)112/6995/5098/63Heart rate (beats per minute)9440-5080-90Temperature (Fahrenheit)99.798.198Respiratory rate (breaths per minute)16-2028-2816-18Oxygen saturation (%)999798Sodium (meq/L)133143136Potassium (meq/L)3.13.23.9Magnesium (meq/L)2.01.51.8Serum creatinine (mg/dL)1.50.670.74Aspartate transaminase (H/L)1073370Alanine transaminase (U/L)742680Alkaline phosphatase (U/L)1229978Total bilirubin (mg/dL)0.90.30.3Troponins (ng/mL)\<0.012\<0.012\<0.012D-dimer (mg/L FEU)211410C-reactive protein (mg/dL)\>205.41.3Interleukin-6 (pg/mL)-16.4-Lactate dehydrogenase (U/L)324496220Ferritin (ng/mL)872\>100640White blood cell count (10\*3/uL)18.73710Hemoglobin (g/dL)11.51111.5Platelet (K/uL)240528407International normalized ratio1.1-1.2P-R interval (ms)150168150QRS duration (ms)728062QTc interval (ms)427650467Figure 1Electrocardiogram of the patient with ventricular fibrillationFigure 1

Discussion {#sec0003}
==========

One study reported ventricular tachycardia (VT)/VF in 5.9% (11/187) of COVID-19 patients ([Table 2](#tbl0002){ref-type="table"} [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009]), with elevated troponin-T increasing risk, suggesting that myocardial injury precipitates arrhythmia[@bib0002]. However, VT/VF also occurs in patients with low troponin, suggesting alternative causes, such as QTc prolonging medication (e.g., hydroxychloroquine)[@bib0002]. Another possibility is the fulminant systemic inflammatory state in sick patients with cardiovascular morbidities and metabolic disarray. Inflammatory cardiac channelopathies, induced by inflammatory markers, can prolong the action potential and cause long QT syndrome and TdP [@bib0010] ^,^ [@bib0011]. Moreover, systemic inflammation can increase risk for ventricular arrhythmia indirectly by inducing a hyper-sympathetic state or inhibiting cytochrome p450[@bib0011]. Other inflammatory responses, such as fever, can trigger undiagnosed conduction diseases or channelopathies, like Brugada syndrome[@bib0012].Table 2Articles describing arrhythmic events in patients with COVID-19Table 2Number of Patients with Event of InterestFirst AuthorDateSample SizeVentricular TachycardiaElevated TroponinsVentricular Tachycardia/Fibrillation Cardiac ArrestVentricular Tachycardia StormGuo\
March 2020\
N=187119--------Goyal\
April 2020\
N=3931------------Kochav\
May 2020\
N=11[\*](#tb2fn1){ref-type="table-fn"}111Chorin\
May 2020\
N=2511[⁎⁎](#tb2fn2){ref-type="table-fn"}--------1Shao\
June 2020\
N=7618------------Bhatla\
June 2020\
N=70010----1----Mitacchione\
July 2020\
N=11[⁎⁎⁎](#tb2fn3){ref-type="table-fn"}--------1[^1][^2][^3]

Reducing this inflammatory state in COVID-19 patients can mitigate arrhythmic events, as well as other morbidity and mortality. Tocilizumab, an anti-interleuken 6 receptor monoclonal-antibody, yielded a survival benefit in COVID-19 patients[@bib0013], [@bib0014], [@bib0015]. Tocilizumab was shown to have a robust shortening of the QTc prolongation induced by abundant inflammatory cytokines in patients with acute rheumatoid arthritis[@bib0016]. Additionally, preliminary reports from ongoing trials indicate toclizumab may reduce adverse myocardial injury in acute inflammatory cardiac injury[@bib0002] ^,^ [@bib0013].

The initial hypothesis regarding our patient\'s VF storm etiology was acute myocarditis; however, with consistently normal troponins, the explanation is likely a constellation of factors, including hypokalemia, hypomagnesemia, bradycardia and long QTc, in the setting of hyper-inflammation ([Figure 2](#fig0002){ref-type="fig"} ). This hypothesis is supported by significantly elevated inflammatory markers. As such, this report suggests that the hyper-inflammatory state in COVID-19 patients can induce ventricular arrhythmias, which may cease abruptly following a reduction in inflammation, in our case from convalescent serum and/or hydrocortisone therapy.[@bib0017] ^,^ [@bib0018] Hence, dampening this fulminant inflammatory condition may prevent or decrease cardiac arrhythmias.Figure 2A Venn diagram illustrating the hypothesis that this patient\'s ventricular tachycardia resulted from a scenario involving a multitude of factors (abnormal labs, renal injury, long QTC, and inflammation). In order for the ventricular tachycardia to occur, these factors need to happen together. Conversely, a normal patient who happens to have a high degree of inflammation will not have ventricular tachycardia if other variables in the Venn diagram are absent. TdP = Torsades de Pointe.Figure 2
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[^1]: The patient had prolonged QTc, heart failure with preserved ejection fraction, diabetes mellitus, and atrial fibrillation

[^2]: The patient was in Torsades de Pointe and on hydroxychloroquine + azithromycin

[^3]: The patient had heart failure with reduced ejection fraction and coronary artery disease
